Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor and Azacitidine as Maintenance Therapy for High-Risk AML/MDS After Allo-HSCT
NCT07779031Phase 2Active, not recruiting
- Sponsor
- Liping Dou
- Start
- May 2025
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Liping Dou. Started May 2025; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07779031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07779031.